Dimension Therapeutics Inc. (NASDAQ:DMTX) shares dropped 8.6% during mid-day trading on Wednesday . The company traded as low as $6.61 and last traded at $6.72, with a volume of 56,146 shares trading hands. The stock had previously closed at $7.35.

DMTX has been the topic of a number of research reports. Cantor Fitzgerald restated a “buy” rating on shares of Dimension Therapeutics in a research report on Wednesday, June 22nd. Jefferies Group initiated coverage on shares of Dimension Therapeutics in a research report on Thursday, June 2nd. They set a “buy” rating and a $12.00 target price on the stock. Zacks Investment Research upgraded shares of Dimension Therapeutics from a “sell” rating to a “buy” rating and set a $7.50 target price on the stock in a research report on Tuesday, May 17th. Canaccord Genuity restated a “buy” rating on shares of Dimension Therapeutics in a research report on Saturday, May 14th. Finally, Citigroup Inc. cut their target price on shares of Dimension Therapeutics from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, March 29th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $17.56.

The company’s market capitalization is $168.40 million. The company’s 50 day moving average price is $7.70 and its 200 day moving average price is $7.78.

Dimension Therapeutics (NASDAQ:DMTX) last released its earnings results on Thursday, May 12th. The company reported ($0.38) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.57) by $0.19. The company had revenue of $2.21 million for the quarter, compared to analysts’ expectations of $2.24 million. Equities analysts predict that Dimension Therapeutics Inc. will post ($1.96) earnings per share for the current year.

In other news, SVP K. Reed Clark sold 5,000 shares of the business’s stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $10.00, for a total value of $50,000.00. Following the transaction, the senior vice president now directly owns 5,000 shares in the company, valued at $50,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

An institutional investor recently bought a new position in Dimension Therapeutics stock. Jennison Associates LLC acquired a new stake in shares of Dimension Therapeutics Inc. (NASDAQ:DMTX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 742,454 shares of the company’s stock, valued at approximately $8,265,000. Jennison Associates LLC owned 2.97% of Dimension Therapeutics as of its most recent filing with the SEC.

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.